The future of biologic agents in the treatment of Sjogren's syndrome

被引：27
|
作者：
Meijer, Jiska M.
Pijpe, Justin
Bootsma, Hendrika
Vissink, Arjan
Kallenberg, Cees G. M.
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Oral & Maxillofacial Surg, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, Groningen, Netherlands
来源：
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY | 2007年 / 32卷 / 03期
关键词：
Sjogren's syndrome; biological agent; treatment; monoclonal antibody; therapy; autoimmune disease;
D O I：
10.1007/s12016-007-8005-6
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjogren's syndrome (SS) and the current availability of various biological agents (anti-TNF-alpha, IFN-alpha, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.
引用
收藏
页码：292 / 297
页数：6
相关论文
共 50 条
  • [1] The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome
    Jiska M. Meijer
    Justin Pijpe
    Hendrika Bootsma
    Arjan Vissink
    Cees G. M. Kallenberg
    Clinical Reviews in Allergy & Immunology, 2007, 32 : 292 - 297
  • [2] Biologic treatment in Sjogren's syndrome
    Sada, Pablo Ruiz
    Isenberg, David
    Ciurtin, Coziana
    RHEUMATOLOGY, 2015, 54 (02) : 219 - 230
  • [3] Present and future of biologic drugs in primary Sjogren's syndrome
    Sambataro, Domenico
    Sambataro, Gianluca
    Dal Bosco, Ylenia
    Polosa, Riccardo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (01) : 63 - 75
  • [4] Treatment of Sjogren's syndrome
    Saraux, A.
    REVUE DE MEDECINE INTERNE, 2010, 31 : S16 - S17
  • [5] Present and novel biologic drugs in primary Sjogren's syndrome
    Fasano, S.
    Isenberg, D. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (03) : S167 - S174
  • [6] Recommendations for the treatment of Sjogren's syndrome
    Valim, Valeria
    Moca Trevisani, Virginia Fernandes
    Pasoto, Sandra Gofinet
    Serrano, Erica Vieira
    Euzebio Ribeiro, Sandra Lucia
    de Alencar Fidelix, Tania Sales
    Vilela, Veronica Silva
    do Prado, Leandro Lara
    Tanure, Leandro Augusto
    Liborio-Kimura, Tatiana Nayara
    de Brito Filho, Odvaldo Honor
    Pimenta de Barros, Liliana Aparecida
    Miyamoto, Samira Tatiyama
    Lourenco, Silvia Vanessa
    Ferreira Silva Santos, Maria Carmen Lopes
    Vieira, Luis Antonio
    Diniz Adan, Consuelo Bueno
    Bernardo, Wanderley Marques
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2015, 55 (05) : 446 - 457
  • [7] Advances in the diagnosis and treatment of Sjogren's syndrome
    Chen, Xiaoyun
    Wu, Huaxun
    Wei, Wei
    CLINICAL RHEUMATOLOGY, 2018, 37 (07) : 1743 - 1749
  • [8] Advances in the diagnosis and treatment of Sjogren’s syndrome
    Xiaoyun Chen
    Huaxun Wu
    Wei Wei
    Clinical Rheumatology, 2018, 37 : 1743 - 1749
  • [9] Mycophenolate for the treatment of primary Sjogren's syndrome
    Chen, Weiqian
    Lin, Jin
    JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2020, 8 (03) : 146 - 149
  • [10] Therapy of Sjogren's syndrome - New aspects and future directions
    Vlachoyiannopoulos, PG
    ANNALES DE MEDECINE INTERNE, 1998, 149 (01): : 49 - 53
12345